Understanding how Legionella pneumophila disrupts protein synthesis in host cells

Characterizing host translation inhibition by Legionella pneumophila

NIH-funded research Johns Hopkins University · NIH-10822046

This study is looking at how the Legionella bacteria, which causes Legionnaires' disease, messes with the way our cells make proteins, and by understanding this process, we hope to find better ways to treat infections caused by this germ.

Quick facts

Grant typeFellowship grant
Study typeNIH-funded research
Funding institutionJohns Hopkins University NIH-funded
Lab location1 site (Baltimore, United States)
Project IDNIH-10822046 on NIH RePORTER

What this research studies

This research investigates how the bacterium Legionella pneumophila, which causes Legionnaires' disease, interferes with the process of protein synthesis in human cells. By examining the toxic proteins that Legionella injects into host cells, the study aims to uncover the mechanisms by which these proteins inhibit translation, a critical process for cell function. The research employs biochemical techniques to analyze the interactions between Legionella's effectors and the host's translation machinery, providing insights into the pathogen's strategy for survival and replication. This understanding could lead to new therapeutic approaches for treating infections caused by this bacterium.

Who could benefit from this research

Good fit: Ideal candidates for participation or benefit from this research would include individuals diagnosed with Legionnaires' disease or those at risk of infection due to underlying health conditions.

Not a fit: Patients with infections caused by other bacteria that do not utilize similar mechanisms of translation inhibition may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to the development of novel treatments for Legionnaires' disease and other infections caused by similar pathogens.

How similar studies have performed: Previous research has shown success in understanding bacterial mechanisms of translation inhibition, but this specific approach to Legionella pneumophila is relatively novel.

Where this research is happening

Baltimore, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.